Mobile App

Google Play Apple Store
Methamphetamine-Associated Pulmonary Arterial Hypertension
AMA/ANCC/ACPE - Clinical Snippet
Methamphetamine-associated pulmonary arterial hypertension (MA-PAH) is a serious and increasingly recognized subtype of pulmonary arterial hypertension linked to methamphetamine use. In this on-demand clinical snippet, Dr. Vijay Balasubramanian delves into the epidemiology, clinical characteristics, and hemodynamic challenges of MA-PAH. Participants will gain insights into the global and U.S. trends of methamphetamine use, its associated cardiopulmonary risks, and the mechanisms contributing to vascular toxicity. In addition, this activity addresses current gaps in treatment strategies, challenges in patient adherence, and the need for more comprehensive management approaches, equipping healthcare providers with knowledge to better diagnose and manage this complex condition.
Review this activity and claim AMA, ANCC, or ACPE credit/contact hour after completion of a brief pretest and post-test/evaluation.

 
Vijay Balasubramanian, MD, MRCP Vijay Balasubramanian, MD, MRCP (UK)
Medical Director
Valley Advanced Lung Disease Institute
Clinical Professor of Medicine
California Health Sciences University

Methamphetamine-associated pulmonary arterial hypertension (MA-PAH) is a serious and increasingly recognized subtype of pulmonary arterial hypertension linked to methamphetamine use. In this on-demand clinical snippet, Dr. Vijay Balasubramanian delves into the epidemiology, clinical characteristics, and hemodynamic challenges of MA-PAH. Participants will gain insights into the global and U.S. trends of methamphetamine use, its associated cardiopulmonary risks, and the mechanisms contributing to vascular toxicity. In addition, this activity addresses current gaps in treatment strategies, challenges in patient adherence, and the need for more comprehensive management approaches, equipping healthcare providers with knowledge to better diagnose and manage this complex condition.
Review this activity and claim AMA, ANCC, or ACPE credit/contact hour after completion of a brief pretest and post-test/evaluation.



 
Vijay Balasubramanian, MD, MRCP Vijay Balasubramanian, MD, MRCP (UK)
Medical Director
Valley Advanced Lung Disease Institute
Clinical Professor of Medicine
California Health Sciences University

 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.

20
Supported by independent educational grants from
United Therapeutics, a public benefit company, Bayer U.S.; Merck & Co., Inc., Rahway, NJ, USA; and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

Launch Date: December 11, 2024
Release Date: December 11, 2024
Expiration Date: November 30, 2025

Mini Module
7841
ClinicalSnippetsPAH(1730x162).gif
False
  • Pulmonology
Pulmonology

CookieConsent

Change Settings